摘要
目的:探索高剂量强度非铂类联合化疗方案对鼻咽癌远处转移的近期疗效,及多疗程巩固交替的治疗方法在鼻咽癌远处转移治疗中的价值。材料及方法:共收治鼻咽癌远处转移患者17例。全部病例第一、二疗程均使用紫杉醇+异环磷酰胺(PI)联合化疗。其后再选择不同的联合化疗方案,每种连用23个疗程交替化疗至68疗程。3周为一疗程。结果:两程PI方案总有效率约82%,其中CR12%;PR70%。所有病例均发生骨髓抑制、脱发。其它不良反应轻微。68程化疗耐受性良好,再获PR4例,10例SD;1例原PD患者病情继续进展。目前2例死亡,3例病情进展,其它患者均已随访29个月无进展,截止98年10月中位生存期9±25个月。结论:高剂量强度PI方案对鼻咽癌远处转移有较好疗效,不良反应可以耐受。多方案交替、多疗程巩固化疗有利于改善预后。
Objective: To evaluate the shortterm therapeutic effects
of high intensity noncisplatinum combination chemotherapy regimen and to explore the
treatment method of multiregimen alternation and multicourse consolidation in the treatment of
distant metastatic nasopharyngeal carcinoma. Methods: There were 17 patients collected and
treated.During the first and second course of treatment,all cases were treated with the
combination chemotherapy including paclitaxel+ifosfamide(PI). Courses were repeated every
three weeks. After two courses,different combination chemotherapy regimen were selected to
treated alternatively until 6 to 8 courses. Results: The total effective rate is 82%(CR 12%and
PR70%) in the two courses of PI regimen. The adverse reactions included serious
myelosuppression and alopecia.Other reactions were different from each cases.All the adverse
reactions did not affect the continual treatment.The tolerance of the patients in 68 courses was
good.Four patients acquired PR again,ten patients kept SD;The only PD patient continued
progressively. Till now, two patients died and 3 cases were progressive, all other patients had
been followedup 2 to 9 months and kept stable.The medium survival time was 925 months until
October 1998 Conclusion: The high intensity PI combination chemotherapy regimen is effective.
Its adverse reactions can be tolerated. The treatment method of multiregimen alternation and
multicourse consolidation can improve the prognosis of distant metastatic nasopharyngeal
carcinoma.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1999年第3期300-302,340,共4页
Chinese Journal of Cancer
关键词
鼻咽肿瘤
远处转移
药物疗法
联合疗法
Nasopharyngeal neoplasm,Combination chemotharapy
Distant
matastases
Paclitaxel
Ifosfamide